scispace - formally typeset
W

Wei Xin Khong

Researcher at Tan Tock Seng Hospital

Publications -  24
Citations -  1399

Wei Xin Khong is an academic researcher from Tan Tock Seng Hospital. The author has contributed to research in topics: Plasmid & Enterovirus 71. The author has an hindex of 12, co-authored 21 publications receiving 1150 citations. Previous affiliations of Wei Xin Khong include National University of Singapore & Singapore Ministry of Health.

Papers
More filters
Journal ArticleDOI

Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures.

TL;DR: SARS-CoV-2 is transmissible in community settings, and local clusters of COVID-19 are expected in countries with high travel volume from China before the lockdown of Wuhan and institution of travel restrictions.
Journal ArticleDOI

Interrupting transmission of COVID-19: lessons from containment efforts in Singapore.

TL;DR: Despite multiple importations resulting in local chains of transmission, Singapore has been able to control the COVID-19 outbreak without major disruption to daily living as mentioned in this paper, and share some early lessons learnt from the experience.
Journal ArticleDOI

A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection.

TL;DR: It is demonstrated that 2-week-old and younger immunodeficient AG129 mice, which lack type I and II interferon receptors, are susceptible to infection with a non-mouse-adapted EV71 strain via both the intraperitoneal (i.p.) and oral routes of inoculation, making this mouse model relevant for EV71 pathogenesis studies and an attractive platform for EV 71 vaccine and drug testing.
Journal ArticleDOI

Sustained High Levels of Interleukin-6 Contribute to the Pathogenesis of Enterovirus 71 in a Neonate Mouse Model

TL;DR: It is demonstrated that IL-6 plays a major role in EV71-induced immunopathogenesis and as there is still neither vaccine nor treatment available against EV71, anti-IL-6 antibody treatment represents a potential therapeutic approach to providing protection from the most severe complications of the disease.